Szemészet, 2015 (152. évfolyam, 1-4. szám)
2015-09-01 / 3. szám
Irodalom 1. Philip G. Conaghan A turbulent decade for NSAIDs: update on current conceptsDof classification, epidemiology, comparative efficacy, and toxicity Rheumatol Int 2012; 32: 1491-1502. 2. Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006; 46 (4): 21-40. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24- hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008; 24 (4): 392-398. 4. Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002; 42 (1): 1-11. 5. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehiclecontrolled clinical trial. Am J Ophthalmol 1999; 127 (3): 253-259. 6. Lane SS, Modi SS, Lehmann RR Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33 (1): 53-58. 7. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac Ophthalmic Solution 0.09% CXibrom) Study Group. Bromfenac ophthalmic solution 0.09% CXibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007; 114 (9): 1653-1662. 8. Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kató S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 2009; 87 (3): 300-305. 9. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of pseudophakic cystoid macular edema. Retina 2010; 30 (2): 260-266. 10. Cable MM (as reported by Charters L). Bromfenac reduces CME in cataract; Ophthalmology Times. June 1, 2010. 10. 11. Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg 2008; 34 (1): 57-63. 12. Almeida DR, Johnson D, Hollands H, et al. Effect of prophylactic nonsteroidal postoperative drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg 2008; 34 (1): 64-69. 13. A Practical Look At The Role of NSAIDs In Ophthalmology March 2011 Ophthalmology Times 2011; 3 (15): Suppl. 14. The Evolving Role of NSAIDs in Cataract Surgery Supplement to Cataract S, Refractive Surgery Today April 2011. 15. West ES, Behrens A, McDonnell PJ, Tielsch JM, Schein OD. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 2005; 112 (8): 1388-1394. 16. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg 1999; 25 (11): 1492-1497. 17. Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg 2004; 30 (4): 752-760. 18. Congdon NG, Schein OD, von Kulajta R Lubomski LH, Gilbert D, Katz J. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2001; 27 (4): 622-631. 19. Singer MA, Trattler WB, Boyer DS, et al. Are nonsteroidal drops safe for long-term use? Poster presented at: American Academy of Ophthalmology Meeting; October 24-27, 2009; San Francisco: CA. Poster 624. Levelezési cím Dn Ács Tamás, e-mail: dracstamas@gmail.com A cikk megjelenését a Valeant Pharma Magyarország Kft. támogatta. A cikk tartalma nem tekinthető a Valeant szakmai vagy egyéb tájékoztatásának vagy állásfoglalásának. A megemlített termék alkalmazására az érvényes alkalmazási előírás az irányadó. 5
